[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611853":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":43,"studyPopulation":43,"armGroups":53,"interventions":66,"overallOfficials":76,"centralContacts":81,"locations":86,"responsibleParty":115,"collaborators":118,"id":124,"slug":43,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":43,"eligibilityCriteria":129,"healthyVolunteers":130,"sex":131,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":43,"studyType":137,"phases":138,"briefSummary":140,"conditions":141,"keywords":43,"overallStatus":88,"whyStopped":43,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},{"fullName":5,"class":6},"Poznan University of Life Sciences","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":28,"otherOutcomes":43},[9,13,16,19,22,25],{"measure":10,"description":11,"timeFrame":12},"Concentrations of blood lipids","Total cholesterol, Triacyglycerols, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesteroll","6 months, two measurements: at month 0 and 6",{"measure":14,"description":15,"timeFrame":12},"Blood glucose concentrations","Blood glucose concentration",{"measure":17,"description":18,"timeFrame":12},"Ageing biomarkers: transcription level of the p16INK4a gene in peripheral blood mononuclear cells","transcription level of the p16INK4a gene in peripheral blood mononuclear cells",{"measure":20,"description":21,"timeFrame":12},"Ageing biomarkers: telomere lenght","telomere lenght measured in DNA isolated from whole blood",{"measure":23,"description":24,"timeFrame":12},"Ageing biomarkers: SA beta galactosidase activity","SA beta galactosidase activity",{"measure":26,"description":27,"timeFrame":12},"Oxidative stress","activities of oxidative stress enzymes in blood",[29,33,36,39],{"measure":30,"description":31,"timeFrame":32},"Body mass","Measured in kg","6 months, two measurements: at month 0, 3 and 6",{"measure":34,"description":35,"timeFrame":32},"Body composition","Body composition will include percent body fat and lean body mass measured with air displacement plethysmography",{"measure":37,"description":38,"timeFrame":32},"Waist and hips circumference","Measured in cm",{"measure":40,"description":41,"timeFrame":42},"Genotype analyisis of the Sirt1 gene","Nucleotite variants at certain genomic position will be analysed","baseline",null,{"allocation":45,"interventionModel":46,"interventionModelDescription":43,"primaryPurpose":6,"observationalModel":43,"timePerspective":43,"maskingInfo":47},"RANDOMIZED","PARALLEL",{"masking":48,"maskingDescription":43,"whoMasked":49},"TRIPLE",[50,51,52],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR",[54,60],{"label":55,"type":56,"description":57,"interventionNames":58},"Experimental: sirtuin activators","EXPERIMENTAL","Sirtuin activators supplementation for 6 months, daily dose of 1278 mg, taken twice a day in a capsulated form. Daily dose will contain: resveratrol - 500 mg, leucin - 467 mg, Epigallocatechin gallate - 100 mg, quercetin - 100 mg, curcuminoids - 100 mg, niacin 10.7 mg. Daily number of capsules will be 2 x 2 = 4.",[59],"Dietary Supplement: Sirtuin activators",{"label":61,"type":62,"description":63,"interventionNames":64},"Placebo comparator: placebo","PLACEBO_COMPARATOR","Placebo will be an inactive substance (maltodextrin) provided in the same-looking capsules as sirtuin activators. Placebo will be administered twice a day, daily number of capsules will be 2 x 2 = 4.",[65],"Dietary Supplement: Placebo",[67,72],{"type":68,"name":69,"description":70,"armGroupLabels":71,"otherNames":43},"DIETARY_SUPPLEMENT","Sirtuin activators","Sirtuin acitivators supplementation for 6 months",[55],{"type":68,"name":73,"description":74,"armGroupLabels":75,"otherNames":43},"Placebo","Placebo supplementation for 6 months",[61],[77],{"name":78,"affiliation":79,"role":80},"Agata Chmurzynska, Professor","Poznan Univeristy of Life Sciences","PRINCIPAL_INVESTIGATOR",[82],{"name":78,"role":83,"phone":84,"phoneExt":43,"email":85},"CONTACT","+486184661","agata.chmurzynska@up.poznan.pl",[87],{"facility":5,"status":88,"city":89,"state":43,"zip":43,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":97,"contacts":98},"RECRUITING","Poznan","Poland","PL",{"type":93,"coordinates":94},"Point",[95,96],16.92993,52.40692,{"lat":96,"lon":95},[99,100,103,105,107,109,111,113],{"name":78,"role":83,"phone":84,"phoneExt":43,"email":85},{"name":101,"role":102,"phone":43,"phoneExt":43,"email":43},"Emilia Zawieja","SUB_INVESTIGATOR",{"name":104,"role":102,"phone":43,"phoneExt":43,"email":43},"Monika Mlodzik-Czyzewska",{"name":106,"role":102,"phone":43,"phoneExt":43,"email":43},"Marcin Sadowski",{"name":108,"role":102,"phone":43,"phoneExt":43,"email":43},"Agata Jankowska",{"name":110,"role":102,"phone":43,"phoneExt":43,"email":43},"Agnieszka Seremak-Mrozikiewicz",{"name":112,"role":102,"phone":43,"phoneExt":43,"email":43},"Grażyna Kurzawińska",{"name":114,"role":102,"phone":43,"phoneExt":43,"email":43},"Agata Muzsik-Kazimierska",{"type":80,"investigatorFullName":116,"investigatorTitle":117,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"Agata Chmurzyńska","Professor",[119,121],{"name":120,"class":6},"Poznan University of Medical Sciences",{"name":122,"class":123},"NutroPharma","INDUSTRY","100611853",false,"NCT07245979","Supplementation With Sirtuin Activators in Women With Increased Body Weight","Assessment of the Effect of Sirtuin Activator Supplementation on Cellular, Metabolic and Anthropometric Parameters in Women","Inclusion Criteria:\n\n* females\n* age: 40-65 years\n* overweight or obese: BMI \\>25 kg\u002Fm2\n\nExclusion Criteria:\n\n* males\n* BMI \\\u003C 25 kg\u002Fm2\n* sirtuin activators administration for 3 months prior to study\n* pregnancy or breastfeeding\n* recent dieting or being on calorie restricted diet\n* receiving pharmacotherapy to treat obesity, diabetes or hyperlipidemia\n* post-bariatric surgery\n* diabetes\n* cancer\n* chronic kidney, liver or autoimmune diseases\n* alcohol addiction",true,"FEMALE","40 Years","65 Years",{"count":135,"type":136},120,"ESTIMATED","INTERVENTIONAL",[139],"NA","The goal of this clinical trial is to learn if the six-month supplementation with sirtuin activators can affect metabolism in 40-to-65-year old women with increased body weight. The main questions it aims to answer are:\n\nDoes sirtuin activators affect lipid and carbohydrate metabolism? Does sirtuin activators affect oxydative stress, immune functions and cell ageing?\n\nResearchers will compare sirtuin activators to a placebo (a look-alike substance that contains no drug) to see if drug sirtuin activators works to improve metabolic status.\n\nParticipants will:\n\nTake sirtuin activators or a placebo every day for 6 months. Visit the university once every 3 months for checkups and tests.",[142],"Obesity & Overweight","2026-05-19",{"date":145,"type":146},"2026-05-22","ACTUAL",{"date":148,"type":146},"2025-10-08",{"date":150,"type":136},"2027-03-01",{"name":5,"class":6},1]